Abstract
Metastasis-directed therapy (MDT) has been proposed as a therapeutic option in oligometastatic PCa patients, in order to delay palliative systemic treatment or even to attain cure in selected patients. This chapter examines the role of metastasectomy after primary treatment failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roehl KA, Han M, Ramos CG, Ann JO, Antenor V, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910ā4.
Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA, Kupelian P. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593ā8.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Urol. 2006 Feb 1;175(2):564.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017 Apr;71(4):630ā42.
Devos G, De Meerleer G, Joniau S. Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol. 2019 Apr 25;
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003 Mar 1;61(3):607ā11.
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET/CT mapping of prostate Cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018 Feb;59(2):230ā7.
GrubmĆ¼ller B, Baltzer P, Dāandrea D, Korn S, Haug AR, Hacker M, et al. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomyādiagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2018;45:235ā42.
Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol. 2004 Jan 1;58(1):3ā10.
Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014 Feb;74(3):297ā305.
Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010 Feb;40(2):107ā11.
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations HHS public access. Nat Rev Urol. 2017;14(1):15ā25.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan 21;13(1):8ā10.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015 Apr 16;520(7547):353ā7.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011 Jun 22;8(6):378ā82.
Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for Oligometastatic prostate cancer recurrence: a prospective, randomized, Multicenter phase II trial. J Clin Oncol. 2018 Feb 10;36(5):446ā53.
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative body radiotherapy (SABR) for Oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018 Oct;74(4):455ā62.
Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N, et al. Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival. J Thorac Dis. 2017 Oct;9(Suppl 12):S1282ā90.
Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2018 Sep;0(0)
Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2018 Oct 31;0(0)
Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L, et al. Salvage lymph node dissection after 68 Ga-PSMA or 18 F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget. 2017;8(48):84180ā92.
Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, et al. Surgery in motion robot-assisted salvage lymph node dissection for clinically recurrent prostate Cancer. 2017
Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, et al. Robotic salvage retroperitoneal and pelvic lymph node dissection for ānode-onlyā recurrent prostate cancer: technique and initial series. BJU Int. 2017;120(3):401ā8.
Devos G, Muilwijk T, Raskin Y, Calderon V, Moris L, Van den Broeck T, et al. Comparison of Peri-operative and early oncological outcomes of robot-assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer Front Oncol. 2019;9:781.
Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large. Multi-institutional Anal Eur Urol. 2019 Jan 1;75(1):176ā83.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, et al. Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. World J Urol. 2019 Mar;12:1ā7.
Weiss RJ, Forsberg JA, Wedin R. Surgery of skeletal metastases in 306 patients with prostate cancer. Acta Orthop. 2012 Feb;83(1):74ā9.
Sanjurjo S, Hamida W, Letesson G, Hustinx R, Gillet P, Andrianne R. RepĆ©rage scintigraphique peropĆ©ratoire dāune mĆ©tastase costale unique dāun adĆ©nocarcinome prostatique opĆ©rĆ©. Prog Urol. 2008 Jun;18(6):402ā5.
Bubendorf L, Schƶpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578ā83.
Gandaglia G, Karakiewicz PI, Briganti A, Passoni M, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325ā34.
Smith CP, Sharma A, Ayala G, Cagle P, Kadmon D. Solitary pulmonary metastasis from prostate cancer. J Urol. 1999 Dec;162(6):2102.
Maebayashi T, Abe K, Aizawa T, Sakaguchi M, Ishibash N, Fukushima S, et al. Solitary pulmonary metastasis from prostate cancer with neuroendocrine differentiation: a case report and review of relevant cases from the literature. World J Surg Oncol. 2015 May 7;13(1)
Gago JP, CĆ¢mara G, DionĆsio J, OpiniĆ£o A. Pulmonary metastasis as sole manifestation of relapse in previously treated localised prostate cancer: three exceptional case reports. Ecancermedicalscience. 2016 Jun 7;10
Chao DH, Higgins JPT, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584ā5.
Ciriaco P, Briganti A, Bernabei A, Gandaglia G, Carretta A, Viola C, et al. Safety and early oncologic outcomes of lung resection in patients with isolated pulmonary recurrent prostate Cancer: a single-center experience. Eur Urol. 2019;75(5):871ā4.
Wang H, Li B, Zhang P, Yao Y, Chang J. Clinical characteristics and prognostic factors of prostate cancer with liver metastases.
Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer: correlation between sites and number of organs involved. Cancer. 1984 Dec 15;54(12):3078ā84.
Wang SC, McCarthy LP, Mehdi S. Isolated hepatic metastasis from prostate carcinoma. Urol Case Rep. 2017 Jan 1;10:51.
Kawai H, Shiba H, Kanehira M, Sakamoto T, Furukawa K, Yanaga K. Successful resection of a solitary metastatic liver tumor from prostate cancer 15 years after radical prostatectomy: a case report. Surg Case Rep. 2017 Dec;3(1)
Dutt N, Bates AW, Baithun SI. Secondary neoplasms of the male genital tract with different patterns of involvement in adults and children. Histopathology. 2000;37(4):323ā31.
Price EB, Mostofi FK. Secondary carcinoma of the testis. Cancer. 1957 May;10(3):592ā5.
Howard DE, Hicks WK, Scheldrup EW. Carcinoma of the prostate with simultaneous bilateral testicular metastases: case report with special study of routes of metastases. J Urol. 1957 Jul;78(1):58ā64.
Patel SR, Richardson RL, Kvols L. Metastatic cancer to the testes: a report of 20 cases and review of the literature. J Urol. 1989 Oct;142(4):1003ā5.
Campara Z, Simic D, Aleksic P, Spasic A, Milicevic S. Metastasis of prostate adenocarcinoma to the testis. Med Arch (Sarajevo, Bosnia Herzegovina). 2016 Jul 27;70(4):318ā20.
Gibas A, Sieczkowski M, Biernat W, Matuszewski M. Isolated testicular metastasis of prostate cancer after radical prostatectomy: case report and literature review. Urol Int. 2015 Feb 4;95(4):483ā5.
Kim SO, Choi YD, Jung Il S, Oh KJ, Im CM, Kang TW, et al. Prostate cancer with solitary metastases to the bilateral testis. Yonsei Med J. 2011 Mar;52(2):362ā4.
Bonetta A, Generali D, Corona SP, Cancarini G, Brenna S, Pacifico C, et al. Isolated testicular metastasis from prostate cancer. Am J Case Rep. 2017 Aug 14;18:887ā9.
da Cunha ML, de Oliveira Rodrigues C, de AraĆŗjo MPL, de Freitas Junior CH, Ferrigno R. Solitary testicular metastasis from prostate cancer. A case report diagnosed by PET/CT with PSMA. Vol. 45, European Journal of Nuclear Medicine and Molecular Imaging. Springer Berlin Heidelberg; 2018. p. 888ā9.
Tu S-M, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, et al. Prostate carcinoma with testicular or penile metastases. Cancer. 2002 May 15;94(10):2610ā7.
Van den Berg GM, Menke HE, Stolz E. Nodules on the glans penis, an unusual metastatic pattern of prostate carcinoma: case report. Genitourin Med. 1986;62(2):126ā8.
Philip J, Mathew J. Penile metastasis of prostatic adenocarcinoma: report of two cases and review of literature Prostateadenocarcinomapenile metastasisquality of life. 2003.
Ciriaco P, Briganti A, Bernabei A, Gandaglia G, Carretta A, Viola C, et al. Safety and early oncologic outcomes of lung resection in patients with isolated pulmonary recurrent prostate Cancer: a single-center experience. Eur Urol. 2019 May 1;75(5):871ā4.
Chao DH, Higgins JPT, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584ā5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Devos, G. et al. (2021). Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment. In: Goonewardene, S.S., Persad, R., Ventii, K., Albala, D., Cahill, D. (eds) Salvage Therapy for Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-57181-8_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-57181-8_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57180-1
Online ISBN: 978-3-030-57181-8
eBook Packages: MedicineMedicine (R0)